Clinical trials have indicated that CD269 (B cell maturation antigen, BCMA) and CD138 (also known as syndecan 1) molecules, which are mostly expressed in mature B cells or plasma cell surfaces, could exert substantial anti-MM activity (34–36). Here, SDC1 is linked to Miyoshi myopathy.